NCT01657513

TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis

Production of Antibodies Against Tnf-alfa Blockers in Patients With Psoriasis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: University Hospital, Gentofte, Copenhagen · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

TNF alfa blockers are widely used for treatment of severe psoriasis. These biologics are well-tolerated with few side effects. Unfortunately not all patients respond adequately to treatment with tnf alfa blockers. Some do not respond at all while others respond initially but gradually lose effect despite increased dose and more frequent administration. The cause of treatment failure is largely unknown and it may be production of tnf-alfa neutralizing antibodies. This has been demonstrated in patients with rheumatoid arthritis and inflammatory bowel disease who lost response after treatment with tnf-alfa blockers.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	subjects will receive either infliximab, adalimumab or etanercept	The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug. The study subjects will receive treatment with one drug only - 1. infliximab or 2. adalimumab or 3. etanercept The consulting dermatologist decides which drug to use according to official guidelines

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-07-01
• First posted: 2012-08-06
• Last updated: 2012-08-06

Locations

2 sites across 2 countries: Denmark, Sweden